Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 219Neoplasms 15Neoplasm Metastasis 12Carcinoma, Intraductal, Noninfiltrating 10Breast Neoplasms, Male 7Breast Diseases 7Breast Carcinoma In Situ 7Advanced Breast Cancer 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Endometrial Neoplasms 5Neoplasms by Site 3Breast Cancer Metastatic 3Uterine Cervical Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasm Female 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Seizures 1Sarcoma 1Recurrence 1Quality of Life 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1

Interventions

endostar protein 1coenzyme Q10 1apatinib 1Yoga 1Ubiquinone 1Tamoxifen 1Referral and Consultation 1Palliative Care 1Oxaliplatin 1Melatonin 1Gardening 1Exercise 1Educational Status 1Diet Therapy 1Chemoradiotherapy 1Capecitabine 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Quality of Life × Anastrozole × Clear all
NCT00784680 2009-05-01

ATAC - Quality of Life Sub-Protocol

AstraZeneca

Phase 3 Completed
308 enrolled

Quality of Life

Data powered by HemOnc (CC BY 4.0) Colophon âš¡